A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
The company blasts the US regulator as weeks of uncertainty for its lead drug in Nash end in a complete response letter.
Inventiva’s mid-stage win has revived hopes for PPAR agonists in the liver disease, although safety questions remain.
Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.
A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
A stumble for Inventiva’s lanifibranor in a rare fibrotic disease could bode ill for its prospects in Nash, and for those of other PPAR agonists.
Demand for new issues remains sluggish - only eight private biotechs managed to pull off an IPO in the first quarter of 2017.